EcoDrugPlus

Nuclear Receptor Subfamily 3 Group C Member 2

Ensembl ID : ENSPVAG00000010910
Gene Symbol: NR3C2
1 Cross references
212 Possible Orthologues:

Nucleotide Binding Oligomerization Domain Containing 2

Ensembl ID : ENSPVAG00000014192
Gene Symbol: NOD2
1 Cross references
166 Possible Orthologues:

Opioid Receptor Delta 1

Ensembl ID : ENSPVAG00000017226
Gene Symbol: OPRD1
1 Cross references
252 Possible Orthologues:

Opioid Receptor Kappa 1

Ensembl ID : ENSPVAG00000013010
Gene Symbol: OPRK1
1 Cross references
262 Possible Orthologues:

Opioid Receptor Mu 1

Ensembl ID : ENSPVAG00000010701
Gene Symbol: OPRM1
1 Cross references
214 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSPVAG00000012219
Gene Symbol: OXTR
1 Cross references
262 Possible Orthologues:

P21 (Rac1) Activated Kinase 4

Ensembl ID : ENSPVAG00000013726
Gene Symbol: PAK4
1 Cross references
163 Possible Orthologues:

Pancreatic Lipase

Ensembl ID : ENSPVAG00000017642
Gene Symbol: PNLIP
1 Cross references
300 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Alpha

Ensembl ID : ENSPVAG00000010498
Gene Symbol: PPARA
1 Cross references
453 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Delta

Ensembl ID : ENSPVAG00000002761
Gene Symbol: PPARD
1 Cross references
418 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Gamma

Ensembl ID : ENSPVAG00000009845
Gene Symbol: PPARG
1 Cross references
405 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha

Ensembl ID : ENSPVAG00000002449
Gene Symbol: PIK3CA
1 Cross references
275 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).